Sarepta Therapeutics (NASDAQ:SRPT) Sees Large Volume Increase

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares saw strong trading volume on Thursday . 51,527 shares traded hands during mid-day trading, a decline of 96% from the previous session’s volume of 1,351,151 shares.The stock last traded at $84.48 and had previously closed at $83.22.

Several research analysts recently issued reports on the stock. Guggenheim raised shares of Sarepta Therapeutics from a “neutral” rating to a “buy” rating in a research report on Wednesday, September 15th. Robert W. Baird assumed coverage on shares of Sarepta Therapeutics in a research report on Thursday, October 7th. They issued a “buy” rating and a $110.00 price target for the company. JPMorgan Chase & Co. raised shares of Sarepta Therapeutics from an “underweight” rating to a “neutral” rating and dropped their price target for the stock from $92.00 to $87.00 in a research report on Thursday, August 5th. Needham & Company LLC reissued a “buy” rating on shares of Sarepta Therapeutics in a research report on Tuesday. Finally, Credit Suisse Group upped their price objective on shares of Sarepta Therapeutics from $75.00 to $100.00 and gave the stock a “neutral” rating in a research note on Tuesday. Eleven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $127.61.

The company has a debt-to-equity ratio of 2.25, a current ratio of 5.33 and a quick ratio of 4.70. The company’s 50 day moving average price is $83.74 and its 200 day moving average price is $77.49. The firm has a market capitalization of $6.72 billion, a P/E ratio of -10.38 and a beta of 1.38.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, August 4th. The biotechnology company reported ($1.02) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.29) by $0.27. Sarepta Therapeutics had a negative net margin of 105.73% and a negative return on equity of 94.90%. The business had revenue of $164.09 million for the quarter, compared to analysts’ expectations of $161.95 million. During the same period in the prior year, the firm earned ($1.93) earnings per share. Sarepta Therapeutics’s revenue was up 19.5% compared to the same quarter last year. On average, research analysts anticipate that Sarepta Therapeutics, Inc. will post -7.46 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Scotia Capital Inc. grew its stake in shares of Sarepta Therapeutics by 1.4% during the second quarter. Scotia Capital Inc. now owns 10,739 shares of the biotechnology company’s stock valued at $835,000 after purchasing an additional 145 shares during the last quarter. Rockefeller Capital Management L.P. boosted its stake in Sarepta Therapeutics by 10.2% in the first quarter. Rockefeller Capital Management L.P. now owns 1,801 shares of the biotechnology company’s stock valued at $134,000 after acquiring an additional 166 shares during the last quarter. NEXT Financial Group Inc boosted its stake in Sarepta Therapeutics by 10.4% in the second quarter. NEXT Financial Group Inc now owns 1,896 shares of the biotechnology company’s stock valued at $147,000 after acquiring an additional 179 shares during the last quarter. Commerce Bank boosted its stake in Sarepta Therapeutics by 7.4% in the second quarter. Commerce Bank now owns 3,499 shares of the biotechnology company’s stock valued at $272,000 after acquiring an additional 242 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. boosted its stake in Sarepta Therapeutics by 7.3% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 5,331 shares of the biotechnology company’s stock valued at $414,000 after acquiring an additional 365 shares during the last quarter. 79.33% of the stock is currently owned by institutional investors and hedge funds.

About Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Read More: What is the S&P/ASX 200 Index?

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.